Beijing Hokuriku Pharmaceutical Co., Ltd. was established in September 1992, mainly engaged in pharmaceutical product development, production and sales. As a Science and Technology, Ministry of Finance and Administration of Taxation jointly identified high-tech pharmaceutical enterprise, Hokuriku Pharmaceutical has been committed to the cause of national health development, adhere to scientific and technological innovation, create wealth for the country, contribute to society, allow enterprises to develop.

company of "segment, the largest share of the" business philosophy, a clear business direction. The main products of contrast agent series, neurological and mental hypoglycemic products. As the first contrast agent developed and launched the first products of enterprises, through technical innovation, process improvement and other means to provide the market with high quality, safe and affordable products for the contrast agent products in the domestic clinical application and development has played a catalytic role. Company's products unique in the field formed the core of competitive advantage, has a high reputation and market influence, covering all provinces, municipalities, hospitals above the county level. Hokuriku focus on marketing personnel, quality training and professional level, and gradually formed a stable, experienced marketing team, in order to better serve doctors and patients.

adhere to people-oriented, in the management of respect, understanding, care, care staff. Training employees enterprise responsibility, social responsibility and family responsibility. Encourage employees to innovate, to form a stable and harmonious internal environment. Meanwhile, from the values, norms of conduct and other efforts to create a unique corporate culture Hokuriku.

companies promote innovation, rigorous style of work, work in the past have made achievements one after another, has been awarded A grade corporate tax credit, Zhongguancun one hundred innovation-oriented pilot enterprises; national invention patent, certificate of national new products, the Beijing Science and Technology Progress Award and other honors; main products also were included in the national Torch Program, the Beijing Torch Program, Beijing and other major industrial projects to obtain financial support at all levels; 2010, the company officially named Beijing development projects across the biomedical industry (G20 works) of the first scale enterprises; in 2010 by the Academy of Social Sciences, China Medical Information Professional Committee and the industry-renowned experts in the selection of the activity , was named "pharmaceutical companies core competencies Top 50" companies.

2009 year 10 30, company as one of the first 28 official at the Shenzhen Stock Exchange GEM listed company has to a new development platform. In the future the company will through technical innovation, management innovation, to promote the academic and professional fund-raising projects, to enhance the company's new drug R & D capabilities, production capacity, operational efficiency, market share and profitability, consolidate and improve the company's core competitiveness.